Model of CE of remdesivir for Covid-19_27Aug20.xlsx (971.01 kB)

MOSAIC: A model to assess the cost-effectiveness of remdesivir for admitted COVID-19 patients in South Africa

Download (971.01 kB)
dataset
posted on 14.09.2020 by Susan Cleary, Cynthia Tamandjou Tchuem, geetesh solanki, Tommy Wilkinson
MODEL STRATEGIES
This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death
Four competing strategies are modelled:
1. The "status quo" summarizes costs and outcomes for patients assuming no dexamethasone or remdesivir
2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming dexamethasone at 6mg/day
3. The "remdesivir" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day
4. The "remdesivr plus dexamethasone" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day plus dexamethasone at 6mg/day
MODEL OUTCOMES
Cost: mean cost (general ward, ICU, dexamethasone and remdesivir as appropriate) per admitted patient from the health care provider's perspective
Health outcomes: mean DALYs and deaths per admitted patient
Other outcomes: mean ICU days and inpatient days per admitted patient
Budget impact: mean costs (or savings) associated with intervention implementation

History

Department/Unit

Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town & Health Systems Research Unit, South African Medical Research Council

Licence

Exports

Logo branding

Licence

Exports